ALGS Overview

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.

Wall Street analysts forecast ALGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALGS is81.67 USD with a low forecast of 20.00 USD and a high forecast of 175.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aligos Therapeutics Inc revenue for the last quarter amounts to 169.00K USD, decreased -73.13

Aligos Therapeutics Inc. EPS for the last quarter amounts to -1.91 USD, decreased -85.40

Aligos Therapeutics Inc (ALGS) has 82 emplpoyees as of March 10 2026.

Today ALGS has the market capitalization of 43.47M USD.